HSJ Article

Deltex Medical Group PLC
18 January 2008



18th January 2008

                            Deltex Medical Group plc

 HSJ article highlights CardioQTM's role in tackling wide variations in lengths
                            of stay in NHS hospitals


18 January 2008 - Deltex Medical Group plc ('Deltex Medical'), the UK's leading
haemodynamic monitoring company, notes that an article in this week's Health
Service Journal (HSJ) has highlighted the role that the Company's products can
play in reducing length of stay for surgical patients.

The article was written by Dr Andy Webb, the medical director of University
College London Hospital (UCLH) NHS Foundation Trust and refers to data compiled
by Dr Foster on the average lengths of stay of patients having bowel or hip
replacement surgery in NHS hospitals in England. This data, commissioned by
Deltex Medical, shows wide variation in lengths of stay. Dr Webb goes on to
highlight the work done at various NHS hospitals, including the Freeman hospital
in Newcastle and UCLH, to improve patients' outcomes and reduce lengths of stay
through a combination of enhanced recovery programmes, oesophageal Doppler
monitoring (using the CardioQ) and keyhole surgery.

The data on NHS lengths of stay for hip replacement surgery and bowel surgery is
available on www.reducinglengthofstay.org. The online version of the HSJ article
is available to registered users on http://www.hsj.co.uk/goodmanagement/2008/01/
solutions_for_reducing_length_of_stay.html


Deltex Medical's Chief Executive, Andy Hill commented:


'The HSJ is widely read amongst NHS managers and the publication of Dr Webb's
article shows the growing profile of our products in delivering solutions to the
challenges facing modern NHS hospitals.'


For further information, please contact:-

Deltex Medical Group plc                         01243 774 837

Nigel Keen, Chairman                             [e-mail]
Andy Hill, Chief Executive                       [e-mail]
Ewan Phillips, Finance Director                  [e-mail]


Gavin Anderson & Company                         020 7554 1400

Deborah Walter                                   [e-mail]
Robert Speed                                     [e-mail]


Charles Stanley Securities                       020 7149 6000

Philip Davies                                    [e-mail]
Russell Cook                                     [e-mail]


Notes for Editors


Deltex Medical manufactures and markets the CardioQTM monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-


   •    Validated the results of the Monitor against known standards for
        measuring cardiac output, demonstrating that the technology works

   •    Proved that the CardioQ works in a wide range of surgical procedures

   •    Demonstrated that the Company's technology provides significant health
        and economic benefits by helping to reduce post-operative complications 
        and length of hospital stays by an average of 30 to 40 per cent for a 
        wide range of patients.


The SupraQTM is an entirely non-invasive device which uses an ultrasound probe
held at the base of the patient's neck to track the flow of blood in the aorta;
it presents the same data as the CardioQ in a similar format and is used for
taking snapshots or monitoring over short periods.

                      This information is provided by RNS
            The company news service from the London Stock Exchange